Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.

FDA and NIH Win Award for IP Licensing of Meningitis Vaccine

USP expresses its support for a consensus-based global approach to the naming of biologics.

USP Supports WHO Biologics Naming Proposal

I Holland, in collaboration with the University of Nottingham and experts from the Laboratory of Biophysics and Surface Analysis, United Kingdom, recently completed a two-year tableting science anti-stick research (TSAR) project, which sought to understand why certain formulations stick to tablet tooling.

Solving Tablet-Sticking Problems with I Holland's Predictive Model

Leading global tablet tooling manufacturer, I Holland has a range of multiple tip punches and dies optimised to meet the requirements of modern tablet production.

I Holland Leading global tablet tooling manufacturer

CALIXAR and VirPath use new manufacturing techniques to create a vaccine for the pandemic flu, influenza A (H1N1), available in 2015.

CALIXAR Collaborates with VirPath to Develop H1N1 Vaccine

Texas A&M dedicates national pandemic influenza vaccine manufacturing facility.

Pandemic Vaccine Facility Dedicated in Texas

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Micronization and other processes are used to obtain optimal particle characteristics for pulmonary and oral solid-dosage delivery.

Need for Particle Engineering Increases

A GPhA report says generic drugs saved the US health system $239 billion in 2013.

Generic Pharmaceutical Association Reports Record Cost Savings

Molecular Profiles has expanded its capsule filling capability following significant investment into new equipment at its clinical manufacturing site in the United Kingdom.

Molecular Profiles Expands Capsule Capability

FDA approved XTANDI for the treatment of metastatic castration-resistant prostate cancer.